3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Carcinoma, Renal Cell
6
Kidney Neoplasms
4
Leukemia, Myeloid, Chronic-Phase
3
Carcinoma, Hepatocellular
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Polycythemia Vera
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Leukemia
2
Hepatitis B, Chronic
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplasms
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
peginterferon alfa-2b
×
Clear all
NCT03554005
2019-07-15
MK-4031-009
Merck Sharp & Dohme LLC
Phase 1
Completed
29 enrolled
11 charts